

# **“Ready for the future?” – Current status of national and cross- country horizon scanning systems for medicines in European countries**

Sabine Vogler



Bundesinstitut  
für Arzneimittel  
und Medizinprodukte

**Schriftenreihe**  
**Health Technology Assessment (HTA)**  
**in der Bundesrepublik Deutschland**

---

**“Ready for the future?” – Current status of national and cross-country horizon scanning systems for medicines in European countries**

---

**Sabine Vogler<sup>1</sup>**

<sup>1</sup> WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich (GÖG/Austrian National Public Health Institute), Vienna, Austria

## Wir bitten um Beachtung

Dieser HTA-Bericht ist publiziert in der DAHTA-Datenbank des BfArM ([www.dimdi.de](http://www.dimdi.de) - HTA) und in der elektronischen Zeitschrift *Health Innovation and Technologies* ([www.egms.de](http://www.egms.de)).

Die HTA-Berichte des BfArM durchlaufen ein unabhängiges Gutachterverfahren. Potenzielle Interessenkonflikte bezüglich der HTA-Berichte werden von den Autoren und den Gutachtern offengelegt. Die Literaturauswahl erfolgt nach den Kriterien der evidenzbasierten Medizin. Die Verantwortung für den Inhalt des Berichts obliegt den jeweiligen Autoren.

Die Erstellung des vorliegenden HTA-Berichts erfolgte gemäß gesetzlichem Auftrag nach Artikel 19 des GKV-Gesundheitsreformgesetzes 2000. Das Thema stammt aus dem öffentlichen Vorschlagsverfahren beim DIMDI, durch das Kuratorium HTA priorisiert und vom DIMDI beauftragt. Der Bericht wurde mit Mitteln des Bundes finanziert.

Das DIMDI wurde gemäß Artikel 16a des Medizinprodukte-EU-Anpassungsgesetzes am 26. Mai 2020 in das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) eingegliedert.

---

Herausgegeben vom  
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)

Kontakt  
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)  
Kurt-Georg-Kiesinger-Allee 3  
53175 Bonn

Tel: +49 228 99 307-0  
Fax: +49 228 99 307-5207

E-Mail: [poststelle@bfarm.de](mailto:poststelle@bfarm.de)  
[www.dimdi.de](http://www.dimdi.de)

Schriftenreihe Health Technology Assessment, Bd. 156  
ISSN: 1864-9645  
1. Auflage 2021  
DOI: 10.3205/hta000156L  
URN: urn:nbn:de:0183-hta000156L4

© BfArM, Köln 2021. Alle Rechte vorbehalten

# Zusammenfassung

## Hintergrund

Dank Horizon Scanning, der systematischen Recherche über neu auf den Markt kommende Gesundheitstechnologien, sind Entscheidungsträger/innen besser auf den Eintritt neuer, möglicherweise hochpreisiger Medikamente in ihr Gesundheitssystem vorbereitet. Ziel dieser Studie ist es, bestehende nationale und länderübergreifende Horizon Scanning-Systeme für Medikamente in europäischen Ländern zu untersuchen.

## Methodik

Expertinnen und Experten von Behörden (Vertreter/innen des „Pharmaceutical Pricing and Reimbursement Information“/PPRI-Netzwerks) in der WHO-Region Europa nahmen an Erhebungen in den Jahren 2014 und 2019 teil und gaben dabei Auskunft über den Umsetzungsstand von Horizon Scanning in ihrem Land (Antworten aus 14 bzw. 44 Ländern). Informationen zu gut ausgebauten Horizon Scanning-Systemen (Stand: 2019) wurden mittels Literaturrecherche ergänzt.

## Ergebnisse

2019 nutzten laut eigener Angabe sechs Länder (Island, Italien, Niederlande, Norwegen, Schweden und das Vereinigte Königreich) Horizon Scanning systematisch, und in vier Ländern (Dänemark, Frankreich, Irland und Österreich) kam Horizon Scanning punktuell zum Einsatz. In den übrigen 34 Ländern fand Horizon Scanning keine Anwendung. Die Ergebnisse der Erhebung des Jahres 2014 waren ähnlich; allerdings waren damals Horizon Scanning-Systeme noch seltener verbreitet. Neu ist die länderübergreifende Kooperation von Staaten, bei denen auch gemeinsam zu Horizon Scanning gearbeitet wird; als führendes Beispiel gilt hier die International Horizon Scanning Initiative (IHSI) der Beneluxa-Zusammenarbeit. Länder mit Horizon Scanning-Systemen zeichnen sich im Allgemeinen dadurch aus, dass diese einen fixen Bestandteil des Arzneimittelsystems, konkret für den Umgang mit neuen Medikamenten, darstellen und eine wichtige Entscheidungsgrundlage dafür bieten, ob in der Folge eine umfangreiche Bewertung mittels eines Health Technology Assessments durchgeführt und/oder Preisverhandlungen aufgenommen werden. Horizon Scanning-Systeme unterscheiden sich zwischen den Ländern hinsichtlich des Zeitpunkts des Scans und der Berichte, der Quellen für einfließende Informationen und der Veröffentlichung der Ergebnisse.

## Schlussfolgerung

Obwohl Horizon Scanning angesichts einiger prägender Erfahrungen in der Vergangenheit als durchaus wichtig erachtet wird, ist die tatsächliche Umsetzung in den europäischen Gesundheitssystemen derzeit sehr spärlich. Dies mag auch daran liegen, dass Horizon Scanning ressourcenintensiv ist. Die Schaffung neuer nationaler und internationaler Horizon Scanning-Systeme bietet die Chance, diese von Anfang an mit einer Evaluation über ihre Auswirkungen auf nachhaltigen Zugang zu leistbaren Medikamenten zu begleiten.

# Abstract

## Background

Horizon scanning aims to systematically identify upcoming health technologies and thus allows policy-makers to be better prepared for the entry of new medicines with possibly high price tags into the national health system. The aim of this study is to survey the existence of national and cross-national horizon scanning systems for medicines in European countries.

## Methods

Experts working in public authorities (members of the Pharmaceutical Pricing and Reimbursement Information/PPRI network) in the WHO European region participated in surveys in 2014 and 2019 and informed about the status of horizon scanning in their country (response rate: 14 and 44 countries, respectively). Identified advanced horizon scanning systems as of 2019 were further investigated based on a literature review.

## Results

In 2019, six countries (Iceland, Italy, the Netherlands, Norway, Sweden, the United Kingdom) reported systematic use of horizon scanning for some new medicines, and four countries (Austria, Denmark, France, Ireland) had some horizon scanning activities ongoing. No systematic use of horizon scanning was reported from the remaining 34 countries. The findings of the survey undertaken five years earlier were similar, with even fewer systems in place. A recent development is the establishment of cross-country initiatives of governments that aim, among others, to jointly perform horizon scanning; the International Horizon Scanning Initiative (IHSI) initiated by the Beneluxa collaboration is the most advanced undertaking in this respect. Countries with systematic use tend to have horizon scanning fully integrated in a system for the management of new medicines, and they use horizon scanning outcomes to inform decisions as to whether or not a Health Technology Assessment will be conducted and price negotiations be started. Differences between existing horizon scanning systems mainly concern the timings of scanning and reporting, the sources for the inputs and the accessibility of the findings.

## Conclusion

There appears to be a discrepancy between the perceived importance of horizon scanning based on some eye-opening examples in the past and its actual implementation in European health systems. The latter is likely attributable to horizon scanning being resource-intensive. The establishment of new national and international horizon scanning systems offers the opportunity to investigate from the start their impact on sustainable access to affordable medicines.

# 1 Scientific article

## 1.1 Introduction

Equitable patient access to affordable and effective medicines is a challenge in Europe and globally. Millions of people in low- and middle-income countries (LMIC) have ever since been struggling to afford medications for themselves and for people they care, which resulted in catastrophic household spending<sup>1-3</sup>. In addition, the last decade has seen the challenge of sustainable and fair access to medicines high on the political agenda, and the debate has been driven by high-income countries with solidarity-based health care systems<sup>4-8</sup>.

This is, to a major extent, attributable to the market entry of new medicines with (very) high price tags, for instance to treat cancers<sup>9-11</sup>. While some new medicines may offer major therapeutic progresses, others do not live up to the expectations and cannot offer substantial (added) therapeutic value<sup>12-14</sup>.

To ensure the financial sustainability of publicly funded health care systems, governments have been applying pricing and reimbursement policies. They are supplemented by Health Technology Assessments (HTA) to help select and prioritise cost-effective treatments<sup>15-18</sup>. Furthermore, demand-side measures which target health professionals and patients such as generic substitution have been implemented with the aim to foster the uptake of lower-priced off-patent medicines<sup>19, 20</sup>. From what is known so far, overall these policies have proven to be successful with regard to defined policy aims such as cost-containment, inclusion of medicines in a benefit's package scheme and promotion of competitiveness in the off-patent markets compared to non-interventions<sup>21,22</sup>. But they have not yet been sufficiently effective to ensure sustainable and equitable access to affordable medicines, and so new policy options are being explored.

In this respect, a kind of a turning point was the hepatitis C medication sofosbuvir with a very high price tag in 2014 which had come rather unexpectedly. Policy-makers openly admitted that they had not been prepared to this new treatment option<sup>23</sup>. In response, several governments called for mechanisms to inform authorities and public payers long in advance of what is the pipeline, to allow for strategic preparation<sup>4, 24</sup>. This widespread interest in early alert systems is like a second birth for horizon scanning, which is not at all new.

Horizon scanning is defined as “systematic identification of health technologies that are new, emerging or becoming obsolete and that have the potential to effect health, health services and/or society”<sup>25</sup>. It is based on a standardised methodology that usually consists of five sequential components (identification, prioritisation, early assessment, dissemination, monitoring)<sup>26</sup>. An emerging health technology in this context is a health technology that has not yet been adopted within the healthcare system (e. g. a medicine in the phase II or III clinical trial, or pre-launch stage, a medical device in the pre-marketing stage), and a new health technology is a health technology that is in the launch, early post-marketing, or early diffusion stages<sup>25</sup>. Researchers and public agencies have been working for decades on identifying and assessing new health technologies, including medicines, and since 1997, representatives from Denmark, the Netherlands, Spain, Sweden and the United Kingdom (UK), with associated representatives from Canada and Switzerland have been collaborating on the exchange of information on the safety and efficacy of the new technologies. Started as a working group, it became the EuroScan International Network hosted by the University of Birmingham in 1999, and in 2017 the legal scientific association of EuroScan International Network registered in Germany was founded<sup>27</sup>.

Policy-makers aim to be informed early enough before new medicines enter the market so that they have sufficient time to take evidence-based strategic decisions and prioritisation, and call for horizon scanning systems.

While there is increasing debate on the need for horizon scanning, there is limited up-to-date knowledge on the current status of the establishment of horizon scanning systems for medicines in the pharmaceutical policy frameworks in European countries.

Against this background, this article surveys governments' initiatives of national and cross-national horizon scanning and early alert systems for medicines with a view to exploring developments over years as well as similarities and differences between existing systems.

## 2 Methods

Scope of the study is a system that allows policy-makers to be informed on upcoming medicines (i. e., a horizon scanning or early alert system). Horizon scanning systems of interest could be national ones or cross-country initiatives. Horizon scanning for other health technologies (e. g. medical devices) was not focus of this research. The study was targeted at the World Health Organization (WHO) European region which comprises 53 countries (including also Central Asian countries).

As in a horizon scanning process, it was aimed to first scan a large number of countries and to identify horizon scanning systems, prioritise and select a few based on defined criteria and comparatively analyse them. To do so, a mixed methods approach was used (Figure 1).




Figure 1: Methods to identify, select and analyse national horizon scanning systems for the scope of this study

Surveys addressing officials in authorities responsible for pharmaceutical pricing and reimbursement in European countries were conducted at two points in time to learn whether or not (advanced) horizon scanning systems for medicines were in place. In 2014 and in 2019 members of the Pharmaceutical Pricing and Reimbursement Information (PPRI) network were addressed to participate in a survey. (Both surveys were part of a larger questionnaire that studied further pricing and reimbursement policies for medicines.) PPRI is a network of representatives of competent authorities for pharmaceutical pricing and reimbursement of medicines in mainly European countries<sup>28</sup>. (At the time of the 2019 survey, the PPRI network comprised 47 countries, thereof the then 28 Member States of the European Union (EU), 16 further countries in the WHO European region (Albania, Armenia, Belarus, Iceland, Israel, Kazakhstan, Kosovo, Kyrgyzstan, Moldova, North Macedonia, Norway, Serbia, Russian Federation, Switzerland, Turkey and Ukraine) and three non-European countries (Canada, South Africa and South Korea). In 2014, the PPRI network comprised 42 countries, thereof 39 countries in the European region. The three countries which are not situated in the European region were excluded from this study. 26 of the then 38 PPRI countries in the European region responded to a questionnaire in 2014 which surveyed policy instruments to manage the entry of new, possibly premium-priced medicines. For the second survey of as December 2019 with the then 44 PPRI countries in the European region, a slightly different methodology was applied. We prefilled a questionnaire with information that PPRI network members had provided and validated in a 2018 survey, and we asked for validation. 26 countries validated the 2019 data, while for the remaining 18 countries validated information relating to the year 2018 is available.

Systematically used national horizon scanning systems as of 2019 were selected as case studies if a sufficient level of information was available to allow for meaningful description.

International horizon scanning systems in Europe were identified through a review of cross-country collaborations of European governments in pharmaceutical policy and subsequent contacts to the representatives of collaborations with horizon scanning activities (or plans) in summer 2018 and – to obtain updated information – again in autumn 2019.

The description of national and cross-national horizon scanning systems is based on a review of published literature, including grey literature such as website information, presentations and technical reports.



### 3 Results

#### Overview of horizon scanning systems

In 2019, six countries of the WHO European region (Iceland, Italy, the Netherlands, Norway, Sweden – only inpatient sector, UK) reported systematic use of horizon scanning for some new medicines. Four further countries (Austria, Denmark, France, Ireland) and Sweden for outpatient medicines had some horizon scanning activities ongoing, however not in a comprehensive, integrated manner in the health system. In the remaining 34 countries no use of horizon scanning as part of the pharmaceutical policy framework was reported; however, Belgium informed on plans to introduce a national horizon scanning system.

Five years earlier, two countries (Iceland and Norway) informed about an ongoing implementation of a national horizon scanning system, while Italy and UK reported their up and running projects already in 2014 (partially missing information for some countries).

**Table 1: Horizon scanning in the PPRI network member countries in 2014 and 2019**

Country	National HS system		Cross-country collaborative activity in HS (2019)
	2014	2019	
Albania	<i>No response to this question</i>	No HS system	No involvement in HS col-lab.
Armenia	<i>Not a PPRI member at that time</i>	No HS system	No involvement in HS col-lab.
Austria	<i>No response to this question</i>	Some HS activities, i. e. an early alert system for cancer medicines	Beneluxa member, but no involvement in IHSI
Belarus	<i>Not a PPRI member at that time</i>	No HS system	No involvement in HS col-lab.
Belgium	No HS system	Plan to introduce a national HS system	IHSI member
Bulgaria	<i>Did not respond</i>	No HS system	No involvement in HS col-lab.
Croatia	<i>No response to this question</i>	No HS system	Member of “Valletta Declaration” that plans to do HS
Cyprus	<i>Did not respond</i>	No HS system	Member of “Valletta Declaration” that plans to do HS
Czech Republic	No HS system	No HS system	No involvement in HS col-lab.
Denmark	<i>No response to this question</i>	Some HS activities	IHSI member; member of “Nordic Pharmaceutical Forum” that plans to do HS
Estonia	No HS system	No HS system	No involvement in HS col-lab.
Finland	<i>No response to this question</i>	No HS system	Observer status in “Nordic Pharmaceutical Forum” that plans to do HS
France	Some HS activities (“narrow HS” done by several institutions)	Some HS activities	No involvement in HS col-lab.
Germany	<i>Did not respond</i>	No HS system	No involvement in HS col-lab.
Greece	No HS system	No HS system	Member of “Valletta Declaration” that plans to do HS
Hungary	No HS system	No HS system	No involvement in HS col-lab.
Iceland	HS system in the process of implementation	Systematic use of HS for new medicines	Member of “Nordic Pharmaceutical Forum” that plans to do HS
Ireland	<i>Did not respond</i>	Some HS activities	IHSI member

Table 1 – continued

Israel	<i>Did not respond</i>	No HS system	No involvement in HS collab.
Italy	HS project in a region (Veneto)	Systematic use of HS for new medicines	Member of “Valletta Declaration” that plans to do HS
Kazakhstan	<i>Not a PPRI member at that time</i>	No HS system	No involvement in HS collab.
Kosovo	<i>Not a PPRI member at that time</i>	No HS system	No involvement in HS collab.
Kyrgyzstan	<i>Not a PPRI member at that time</i>	No HS system	No involvement in HS collab.
Latvia	No HS system	No HS system	No involvement in HS collab.
Lithuania	<i>Did not respond</i>	No HS system	No involvement in HS collab.
Luxembourg	<i>No response to this question</i>	No HS system	Beneluxa member, but no involvement in IHSI
Malta	No HS system	No HS system	Member of “Valletta Declaration” that plans to do HS
Moldova	<i>Did not respond</i>	No HS system	No involvement in HS collab.
Netherlands	<i>No response to this question</i>	Systematic use of HS for new medicines	IHSI member
North Macedonia	<i>Did not respond</i>	No HS system	No involvement in HS collab.
Norway	HS system in the process of implementation	Systematic use of HS for new medicines	IHSI member; member of “Nordic Pharmaceutical Forum” that plans to do HS
Poland	<i>No response to this question</i>	No HS system	No involvement in HS collab.
Portugal	<i>Did not respond</i>	No HS system	IHSI member; member of “Valletta Declaration” that plans to do HS
Romania	<i>Did not respond</i>	No HS system	Member of “Valletta Declaration” that plans to do HS
Russian Federation	<i>Not a PPRI member at that time</i>	No HS system	No involvement in HS collab.
Serbia	<i>No response to this question</i>	No HS system	No involvement in HS collab.
Slovakia	<i>No response to this question</i>	No HS system	No involvement in HS collab.
Slovenia	No HS system	No HS system	Member of “Valletta Declaration” that plans to do HS
Spain	<i>No response to this question</i>	No HS system	Member of “Valletta Declaration” that plans to do HS
Sweden	<i>No response to this question</i>	Systematic use of HS for new medicines in the inpatient sector and some HS activities for outpatient medicines	IHSI member; member of “Nordic Pharmaceutical Forum” that plans to do HS
Switzerland	No HS system	No HS system	IHSI member
Turkey	<i>Did not respond</i>	No HS system	No involvement in HS collab.
Ukraine	<i>Did not respond</i>	No HS system	No involvement in HS collab.
United Kingdom	UK PharmaScan (HS database)	Systematic use of HS for new medicines	No involvement in HS collab.

HS = Horizon Scanning. HS collab. = Cross-country collaboration engaged in HS-activities.

IHSI = International Horizon Scanning Initiative. PPRI = Pharmaceutical Pricing and Reimbursement Information.

Some countries were not yet PPRI network member in 2014 and thus not included in the survey of that year.

At cross-country level, some collaborations (e. g. Nordic Pharmaceutical Forum, Valletta Declaration) plan to work jointly on horizon scanning. At the time of writing, the sole cross-country system established is the International Horizon Scanning Initiative of the Beneluxa Initiative. Its members are, to some extent, countries (e. g. the Netherlands, Norway) that already have a national horizon scanning system (Table 1).

### Details of national horizon scanning systems with systematic use

National horizon scanning systems of the countries that reported systematic use (except Iceland) are described in further detail in the following (comparative overview in Table 2).

**Table 2: Dimensions of horizon scanning in countries with its systematic use**

Country	Name	Since	Institution	Customer(s)	Aim	Scope	Timing	Data sources	Criteria	Accessi- bility	Source
Italy	Italian Horizon Scanning Project (IHSP)	2006	Veneto Regional Health Unit	Veneto region & further regions (payers), nat. Medicines Agency	To inform reimbursement decisions, to provide directions to regions for planning	Medicines and medical devices with medicated coating	36 m. before EMA MA – annual report  18 m. = biannual report  12 m. = ad-hoc for any new product	Publicly accessible data sources  No inputs of industry	No explicit filtration and prioritisation criteria	Reports and database accessible for customers	29-32, 34
Netherlands	Horizonscan+	2017 (2012–2017: a light version)	Dutch Healthcare Institute	Dutch Ministry of Health	To identify innovative medicines, to learn about expected list prices, volumes and indication extensions to ensure informed price negotiations	Medicines for outpatient and inpatient use	Two years before MA	Publicly accessible data and involvement of experts (working groups)	“Financial risk” (budget impact)	Publicly available website <sup>36</sup>	34, 35
Norway	“Metodevarsling” (Horizon Scanning) as part of the “Nye metoder” (New health technologies) system	2013	Norwegian Medicines Agency in collaboration with the Norwegian Institute of Public Health	“Commissioning Forum” (representing the regions and federal state)	To inform the next actions to be taken which can be a mini-HTA at hospital level, single HTA or full HTA at national levels as basis for procurement	New “methods” (any health technology) in specialist health care, e.g. hospital medicines – new active substances and indication extensions. Since 2018, also for reimbursed outpatient medicines	Medicines: as early as possible before MA (but with sufficient documentation)  Medical devices: around CE mark  Not routinely updated	Publicly accessible data and through collaboration with international players.  Any stakeholder can and is expected to provide input	Innovation, benefits, budget impact, use in specialist health service	Publicly accessible website MdyNytt <sup>41</sup>	37-40

Table 2 - continued

Sweden	Framtids-spaning (Horizon scanning)	2009	Swedish Association of Local Authorities and Regions (SKL)	Regions (payers), nat. P+R agency	To inform to payers and authorities so that they can decide on the follow-up processes (managed introduction of a medicines based on full HTA or not)	Inpatient medicines	At least one to two years before MA (preferable phase II or III)	Several sources (e. g. international agencies, publications, clinical experts and pharmaceutical industry)	Several filtration criteria (e. g. size of patient population, severity of the disease, expected patient outcomes, possible innovation in treating the disease, impact on treatment costs, possible need for reorganisation of the health care system, safety issues, media/public interest, legal, ethical or political issues)	Early assessment reports published online <sup>46</sup>	34 42-45
UK/ England	Horizon scanning (no specific name)	2006 (as HS system in the NHS)	NIHR HSRIC	Key: NICE and other HTA bodies  Other: Health service policy-making bodies (e. g. DH)	To provide advance notice to health service policy-making bodies of significant, new emerging health technologies, including medicines	Any health technologies, including medicines (for outpatient and inpatient use)	Up to three years prior launch in the NHS (products in clinical phase II, III and pre-launch), aiming to collect information 24 to 30 m. before launch  Brief report to NICE at least 20 m. before launch	Mainly:  UK PharmaScan database (fed by MAH, very restricted access)  Meetings with industry (regular "pipeline meetings", ad-hoc)	Appropriateness for NHS, within defined timelines (to MA and launch).  Completeness is a major performance indicator.	Limited to defined NHS health professionals and administration	34, 47, 49-53

DH = Department of Health. EMA = European Medicines Agency. HS = Horizon Scanning. HTA = Health Technology Assessment. m. = months. MA = Marketing Authorisation. MAH = Marketing Authorisation Holder. nat. = national. NHS = National Health Service. NICE = National Institute for Health and Care Excellence. NIHR HSRIC = Horizon Scanning Research and Intelligence Centre of the National Institute for Health Research. P+R = Pricing and Reimbursement.

One of the oldest horizon scanning systems is the **Italian** Horizon Scanning Project<sup>29-32</sup>. Established in the Veneto Regional Health Unit in 2006, it aims to inform payers (the Veneto region and other regions) and the national Medicines Agency AIFA (Agenzia Italiana del Farmaco) on upcoming medicines as well as medical devices with medicated coating. It offers three different types of reports at different timings: 36 months before the potential market authorisation granted by the European Medicines Agency (EMA), a report is submitted to AIFA that mainly contains information on upcoming medicines, phase II trial data and the indications of ongoing phase III trials. 18 months before possible EMA authorisation, a report mainly for internal purposes assesses available results of the first phase III completed trials. A New Product Information report is delivered twelve months before possible EMA authorisation, and it critically assesses available data on efficacy and safety of the new medicines versus current standards<sup>29, 33</sup>. Data are made available in the CINECA platform which is a closed platform of Italian regions<sup>34</sup>.

Since 2012, the **Netherlands** have made use of horizon scanning. In the first years, it used to be a rather “light horizon scanning system”<sup>34</sup> and mainly relied on the results of other horizon scanning institutions such as the US Agency for Healthcare Research and Quality (AHRQ). In 2017, Horizonscan+ was launched, and the Ministry of Health tasked the umbrella organisation for the health insurers, the National Healthcare Institute (ZINL), to coordinate this expanded system. Horizonscan+ aims to identify new potentially innovative medicines for outpatient and inpatient use two years ahead of marketing authorisation. It also aims to learn about expected list prices and volumes of these new medicines as well as indication extensions of existing innovative medicines<sup>35</sup>. Information is publicly accessible through a dedicated ZINL website in Dutch<sup>36</sup>.

**Norway** established the “National System for Managed Introduction of New Health Technologies within the Specialist Health Service” (“Nye Metoder”) in 2013<sup>37</sup>. It aims to ensure a consistent process for all new health technologies, including medicines and medical devices, in hospital care. A key component is the systematic use of health technology assessments for all new health technologies in different formats (either mini-HTA done by hospitals, single technology assessment against a comparator done by the Norwegian Medicines Agency or full HTA to compare various methods performed by the Norwegian Institute of Public Health). A horizon scanning notification (or a proposal of a stakeholder) guides a committee of representatives from the federal state and regions (payers) on their decision about the type of HTA to be performed. The Norwegian Medicines Agency prepares the horizon scanning notifications for medicines, assisted by literature reviews provided by the Norwegian Institute of Public Health<sup>37-40</sup>. Medicines and other “methods” identified in the horizon scanning exercise are published in an open access database (MedNytt) of the Norwegian Institute of Public Health, which is updated ten times a year<sup>40,41</sup>. Since January 2018, findings of horizon scanning relating to medicines for outpatient use can also result in HTA<sup>38</sup>.

Similar to the processes in the Netherlands and Norway, horizon scanning in **Sweden** is integrated in the process of managed introduction of new medicines in hospitals. It aims to inform the regions who are the payers, by providing a basis for their decision on whether or not a “managed introduction” based on a full HTA or company collaboration is needed for a specific medicine. Horizon scanning is done by the four largest regions (Västra Götaland, Östergötland, Stockholm and Skåne), through the Horizon Scanning working group (one representative of the each of the four regions and a coordinator), as part of the “Collaboration Model” framework coordinated by the overarching Swedish Association of Local Authorities and Regions<sup>34,42</sup>. The working group members regularly monitor sources, such as international and national agencies. Industry input is gained through pipeline hearings and scanning of websites<sup>43</sup>. The Horizon Scanning working group prepares the first step of the filtration process of the aggregated data at least one to two years before marketing authorisation. Filtration is finalised by the decision on whether or not an early assessment report (“tidig bedömningsrapport”), which describes the current state of knowledge, will be produced (available around six months before marketing authorisation)<sup>43,44</sup>. Filtration is informed by inputs of clinical experts of the counties and considers several criteria<sup>42,45</sup>. Outcomes of horizon scanning such as early assessment reports and medicines identified for early assessment reports are published on the website of the Health and Medical Administration of the Stockholm region<sup>46</sup>.

The **UK** has a long history of horizon scanning, and UK’s countries have their own systems in place. In **England**, horizon scanning is the responsibility of the Horizon Scanning Research and Intelligence Centre of the National Institute for Health Research (NIHR HSRIC), which was called National Horizon Scanning Centre (NHSC) until 2012. Established as an independent research team at the University of Birmingham

in 1998, it was incorporated as a research program within the NIHR in 2006<sup>47</sup>. It provides an advance notice of new and emerging health technologies and interventions that are likely to have a significant impact on the National Health Service (NHS) and/or on patients within the next two to three years. The key customer is National Institute for Health and Care Excellence (NICE), which expects to receive a brief report on new products at least 20 months before launch. Two major approaches are applied in the identification process: a general routine identification through a “horizontal scan” and an in-depth scanning and review in defined areas with known multiple or complex developments and for patient groups with significant or unmet needs<sup>34</sup>. In addition to publications (e. g. scientific journals, other horizon scanning organisations), the key information sources are “pipeline meetings” held with industry and the UK PharmaScan database. This database was established by the Department of Health and the Association of the British Pharmaceutical Industry, as a commitment in the 2009 Pharmaceutical Price Regulation Scheme to establish a single, unified horizon scanning process to identify new technologies in development by the industry<sup>48</sup>. Operational since 2010, it was funded by the Department of Health and horizon scanning bodies and is hosted by NICE. Access to UK PharmaScan, which is expected to be fed by pharmaceutical companies, is highly restricted to a few institutions such as NICE, NIHR HSRIC, further horizon scanning institutions in Wales, Scotland and Northern Ireland and UK Medicines Information<sup>49-51</sup>. The latter provides a horizon scanning service by offering reports such as “Prescribing Outlook” to health care professionals and NHS budget holders (limited access for those working in the NHS)<sup>34</sup>. Scotland and Wales have separate, partially complementary horizon scanning systems performed by the HTA institutions Scottish Medicines Consortium (SMC)<sup>52</sup> and All Wales Medicines Strategy Group (AWMSG)<sup>53</sup>, respectively.

### **International Horizon Scanning Initiative (IHSI)**

The International Horizon Scanning Initiative (IHSI) was established in October 2019 as an independent legal entity that will provide outcomes to its member countries. It was initiated by the Beneluxa Initiative, a cross-national collaboration of five European countries (Belgium, Netherlands, Luxembourg, Austria, Ireland), but as a separate area for collaboration independent from the status of being a Beneluxa member. The Beneluxa Initiative invited further countries to participate in collaborating in horizon scanning, without having to join the Beneluxa Initiative<sup>54</sup>. IHSI started with eight countries: Belgium, the Netherlands, Denmark, Ireland, Norway, Portugal, Sweden, Switzerland, and further countries expressed interest<sup>55</sup>.

In preparation for IHSI, the Belgian Health Care Knowledge Centre (KCE) was commissioned to develop a model for a joint horizon scanning system and to assess the feasibility of the proposed methodology for Belgium. KCE recommended to set up a central horizon scanning unit (either to be newly established or as an expansion of the horizon scanning activities of an existing unit), to provide sufficient resources, to pilot the proposed methodology and to perform an evaluation with subsequent adjustments<sup>34</sup>.

End of 2018, an open market consultation was conducted to inform market operators about an upcoming public procurement procedure for setting up an international horizon scanning system and to obtain market operators’ input on the viability of the procurement design and conditions<sup>56</sup>.

In Q1/2020, a tender was launched with the aim to select a third party provider tasked with building and implementing the IHSI Joint Horizon Scanning Database, which will consist of two key elements: the technical infrastructure to host the database, and a scientific component relating to the data collection exercise which is intended to continuously populate the database. The database should be up and running by end of 2020, and first datasets are expected at the beginning of 2021<sup>57</sup>.

## 4 Discussion

To the author's knowledge, this is the first survey on the existence of national and cross-national horizon scanning systems throughout the WHO European region. Previous studies – some of which performed more than 15 years ago – only considered existing horizon scanning systems, usually with a focus on specific aspects, such as selection or search methodologies<sup>34, 58, 59</sup>. This study, which applied a wide geographic scope, showed that national systems with systematic use of horizon scanning for emerging health technologies are in place in a rather limited number of countries. As a trend, these are high-income countries that have also been exploring a range of other policy options along the value chain<sup>28</sup>. As horizon scanning systems are resource-intensive and their establishment and maintenance require capacity of experts and sufficient funding, it is not surprising that higher-income countries were among the first ones to establish these systems. They could also build on horizon scanning activities performed earlier by research and HTA institutions such as in the frameworks of the European Network for Health Technology Assessment (EUnetHTA) project or the EuroScan collaboration.

At the same time, there appears to be high interest of numerous countries in an early alert of what is in the pipeline. One option to gain access to horizon scanning outcomes in the case of limited capacity and resources is through collaborative efforts: Several countries (members of the Beneluxa Initiative and beyond) joined the newly launched International Horizon Scanning Initiative. Further cross-country collaborations, which were established in recent years (e.g. Valletta Declaration, Nordic Pharmaceutical Forum), are committed to work together on horizon scanning but have not yet started implementation; interestingly, some member countries of the mentioned cross-country collaborations also joined IHSI. Collaborative efforts help containing the costs, which may be substantial: in the 2017 feasibility study for a collaborative horizon scanning system of the Beneluxa Initiative, which then resulted in establishing the IHSI, an annual budget amounting to eight to ten full-time equivalents was established<sup>34</sup>.

Countries with advanced horizon scanning systems tend to establish them in an integrative manner in the respective pharmaceutical policy framework: As the country examples of this study show, horizon scanning is applied as a first, fundamental step in the system for managing the entry of new, possibly high-priced medicines in the national health service or social insurance system. The findings of systematic application of horizon scanning are used, frequently in a standardised way, to decide on the further path of identified medicines, i. e. whether or not a full HTA will be performed, price negotiations will be launched and/or managed-entry agreements will be concluded. It is obvious that budget impact considerations play a role, and this review confirmed that they are explicitly or implicitly used for the filtration and prioritisation process, in addition to other criteria.

To contain the cost for the establishment and maintenance of horizon scanning systems, countries could limit their scope (e. g. on oncology medicines in Austria<sup>60-62</sup>), or focus the identification strategies on defined therapeutic areas. An established horizon scanning system, which has developed a methodological basis, can rather easily extend its scope if there is need and/or resources are provided. For instance, the Austrian HTA institution (named Austrian Institute for Health Technology Assessment since 2020), which has managed the Horizon Scanning System in Oncology since 2007, established a Horizon Scanning System for COVID-19 medicines and vaccines in Q1/2020 and published the first report in April 2020.

The study findings point to the importance of smooth coordination and well-functioning communication between technical experts and policy-makers if horizon scanning shall support the managed entry of new medicines. Some authors see here an enhanced role of the HTA community to provide for a better bridging<sup>63</sup>. Furthermore, to ensure that information actually reaches the policy-makers, optimised information flows and deliverables are needed. In fact, some of the studied horizon scanning systems have defined deliverables targeted at policy-makers (e.g. brief new product information reports) while some other reports are rather internal (e. g. Italy). In addition, a well-defined path, such as in the Netherlands and Norway, to manage the introduction of new medicines with deadlines for submitting the reports and scheduled meetings, in which a committee considers the horizon scanning results, likely enhances policy relevance. If horizon scanning is done by research groups that are not connected to the “system” (though publicly funded), there may be the risk that the outcomes will not be considered in policy decisions. This would constitute a waste of resources, and ignorance of the work by the policy-makers is frustrating for the experts who did

the scanning. In England, an independent academy-based research group on horizon scanning was integrated in an NHS institution in 2006<sup>47</sup>, which may have strengthened its policy relevance.

Besides coordination and cooperation, Norway considers transparency as another success factor of their “New Methods” system<sup>64</sup>. Regarding the publication of outcomes, the studied countries apply different approaches: while Norway, Sweden and the Netherlands present their findings on publicly accessible websites and thus support information exchange among countries, Italy and UK share the findings only with professionals and experts in their NHS system. In contrast, the newly launched International Horizon Scanning Initiative aims to solely use publicly accessible information, and this would allow their founders to publish it without limitation should they decide to do so<sup>65</sup>. At national levels, with regard to the confidentiality level of the data sources different approaches were identified between the countries: while some countries considered solely published information, others combined open access information with industry input. The latter was, among others, gained in “pipeline meetings” with pharmaceutical companies that are held in Sweden and the UK. In addition, the UK established the UK PharmaScan database. But its benefit of providing a combined data source for the different countries of the UK is likely undermined by its dependency on the pharmaceutical companies’ willingness to feed the database. It was reported that frequently companies need prompting to complete the database and that not all companies are registered users<sup>34</sup>. In particular, it is interesting to note that the Department of Health funds UK PharmaScan but does not have access to it<sup>51</sup>.

Finally, horizon scanning is usually targeted at identifying emerging new, possibly innovative health technologies, including medicines. However, for understanding the market, it is also important to know when (less expensive) alternatives will be launched and can contribute, due to competition, to savings in public budgets. Obtaining information on the date of the patent expiry is another challenge for governments. In this respect, the emergence of therapeutic equivalents could constitute an added value of horizon scanning systems. The English system, for instance, also scans for first biosimilar medicines of the indication<sup>34</sup>.

## Limitations

The study has some limitations. The PPRI surveys were focused on identifying the existence of horizon scanning systems but did not investigate details of existing systems. Thus, further sources had to be consulted.

The response rate to the respective question on the existence of a horizon scanning system was rather low in the 2014 survey which overall limits the meaningfulness of this survey.

Despite its systematic use, the Icelandic horizon scanning system could not be included in the more detailed comparative description due to lack of data.

The WHO European region consists of 53 countries. Given the difficulties to obtain information from some smaller countries and Central Asian countries (which are also part of the WHO European region), the study was limited to the 44 PPRI countries in the European region (missing countries include mini states such as Andorra, Liechtenstein or Monaco and former Soviet Union countries such as Azerbaijan or Turkmenistan).

While the concept of a (national) horizon scanning system was defined in the surveys, it was up to the respondents to classify ongoing horizon scanning activities as a horizon scanning system. It is acknowledged that other respondents might have considered horizon scanning activities, such as those undertaken by the HTA institution in Denmark<sup>66</sup>, as systematic use of an horizon scanning use.



## 5 Conclusions

The study showed that, while horizon scanning is overall considered as an important policy tool, in particular with regard to contributing to ensuring patient access to new, possibly innovative medicines, only a few European countries actually have an advanced horizon scanning system in place. Systematic use of horizon scanning is resource-intensive, requires expertise in methods and access to data sources, and this may explain the lag in its implementation. Countries with a systematic use of horizon scanning started establishing their horizon scanning system in the last decade or even earlier, and most of them have integrated it into their national pharmaceutical pricing and reimbursement system, with the aim to use the outcomes strategically to inform the next steps such as assessment as well as pricing and reimbursement decisions.

The analysis highlighted that existing horizon scanning systems differ between European countries. The design of the horizon scanning systems varies, among others, with regard to the methodology applied, confidentiality of the data sources and the dissemination strategy. This will, in return, impact the uptake of the findings by other stakeholders in the country and by other countries.

With the establishment of new national horizon scanning systems and the use of the outcomes from cross-country collaborative systems such as the IHSL, it is advised to monitor their performance as well as to share experiences to allow lessons learning for the future. In particular, it is recommended studying the effects of different designs of horizon scanning systems on improving sustainable and equitable access to affordable medicines.

## 6 References

- [1] Arsenijevic J, Pavlova M, Rechel B, Groot W. Catastrophic Health Care Expenditure among Older People with Chronic Diseases in 15 European Countries. *PloS one*. 2016;11(7): e0157765.
- [2] Cylus J, Thomson S, Evetovits T. Catastrophic health spending in Europe: equity and policy implications of different calculation methods. *Bulletin of the World Health Organization*. 2018;96(9): 599.
- [3] Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. *The Lancet*. 2003;362(9378): 111-7.
- [4] Council of the European Union. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States. 17 June 2016. Available from: <https://www.consilium.europa.eu/en/press/press-releases/2016/06/17/epsco-conclusions-balance-pharmaceutical-system/> (accessed 1 March 2019).
- [5] United Nations Secretary General's High-Level Panel on Access to Medicines. Report of the United Nations Secretary General's High-Level Panel on Access to Medicines. Promoting innovation and access to health technologies. September 2016.
- [6] Vogler S. Fair prices for medicines? Exploring competent authorities' and public payers' preferences on pharmaceutical policies. *Empirica*. 2019.
- [7] WHO. Fair Pricing Forum. 2017 Meeting Report. Geneva: World Health Organization, 2017. Available from: [http://www.who.int/medicines/access/fair\\_pricing/FairPricingForum2017MeetingReport.pdf?ua=1](http://www.who.int/medicines/access/fair_pricing/FairPricingForum2017MeetingReport.pdf?ua=1) (accessed 1 March 2019).
- [8] WHO. Fair pricing forum 2019 meeting report: Johannesburg, South Africa, 11-13 April 2019. World Health Organization, 2019. Available from: <https://apps.who.int/iris/bitstream/handle/10665/326407/WHO-MVP-EMP-IAU-2019.09-eng.pdf> (accessed 6 June 2020).
- [9] Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. *Blood*. 2013;121(22): 4439-42.
- [10] Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. *PLoS Med*. 2016;13(5): e1002032.
- [11] Light DW, Kantarjian H. Market spiral pricing of cancer drugs. *Cancer*. 2013;119(22): 3900-2.
- [12] Davis C, Naci H, Gurrupinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. *BMJ*. 2017;359: j4530. Epub 2017/10/06.
- [13] Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the \$440 billion question. *Journal of the National Cancer Institute*. 2009;101(15): 1044-8.
- [14] OECD. New Health Technologies: Managing Access, Value and Sustainability, OECD Publishing; Paris: OECD Publishing; 2017.
- [15] Oortwijn W, Jansen M, Baltussen R. Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe. *International journal of health policy and management*. 2020;9(1): 27-33.
- [16] Sorenson C, Drummond M, Borlum F, Busse R. How can the impact of health technology assessments be enhanced?: World Health Organization; 2008.
- [17] Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in Health Technology Assessment in eight European countries. *Rare Diseases and Orphan Drugs: An International Journal of Public Health*. 2014;1(3): 86-97.
- [18] World Health Organization. 2015 Global Survey on Health Technology Assessment by National Authorities (accessed 5 February 2018). Geneva, 2015.
- [19] Vogler S, Haasis MA, Zimmermann N. PPRI Report 2018. Vienna: Pharmaceutical Pricing and Reimbursement Information, 2019.
- [20] Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. *Applied Health Economics and Health Policy*. 2017;15(3): 1-15.

- [21] Wettstein DJ, Boes S. Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review. *Applied Health Economics and Health Policy*. 2018.
- [22] WHO. WHO Guideline on Country Pharmaceutical Pricing Policies. Geneva: World Health Organization, 2013.
- [23] Vogler S, Zimmermann N, Ferrario A, Wirtz VJ, de Joncheere K, Pedersen HB, et al. Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. *Journal of Pharmaceutical Policy and Practice*. 2016;9(1): 1.
- [24] Vogler S, Paris V, Panteli D. Ensuring access to medicines: How to redesign pricing, reimbursement and procurement? Policy Brief 30. Mossialos E. Copenhagen: World Health Organization, 2018.
- [25] WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Glossary of pharmaceutical terms. Vienna: Austrian National Public Health Institute (GÖG), 2020. Available from: <https://ppri.goeg.at/ppri-glossary> (accessed 2 April 2020).
- [26] Wild C, Langer T. Horizon Scanning System (HSS). An Overview. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA), 2006.
- [27] Euroscan. About Euroscan. Available from: [https://www.euroscan.org/index.php?option=com\\_content&view=article&id=3&Itemid=113&lang=en](https://www.euroscan.org/index.php?option=com_content&view=article&id=3&Itemid=113&lang=en) (accessed 6 June 2020).
- [28] Vogler S, Leopold C, Zimmermann N, Habi C, de Joncheere K. The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative—experiences from engaging with pharmaceutical policy makers. *Health Policy and Technology*. 2014;3(2): 139–48.
- [29] Joppi R, Demattè L, Menti AM, Pase D, Poggiani C, Mezzalana L. The Italian horizon scanning project. *European Journal of Clinical Pharmacology*. 2009;65(8): 775-81.
- [30] Joppi R, Pase D, Poggiani C. Italian Horizon Scanning Project. *Giornale Italiano di Health Technology Assessment*. 2013;6(1): 11-21.
- [31] Joppi R, Demattè L, Pase D, Poggiani C, Mezzalana L. Horizon Scanning Activities. Managed introduction of new medicines. III° PIPERSKA Workshop, 11–13 May 2015 - Warsaw, Poland. 2015. Available from: [http://www.piperska.org/sites/default/files/Joppi\\_Horizon\\_scanning.pdf](http://www.piperska.org/sites/default/files/Joppi_Horizon_scanning.pdf) (accessed 31 May 2020).
- [32] Marangi M, Ivanovic J, Pistritto G. The horizon scanning system at the Italian Medicines Agency. *Drug discovery today*. 2019.
- [33] WHO Regional Office for Europe. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Copenhagen: World Health Organization, 2015.
- [34] Lepage-Nefkens I, Douw K, Mantjes G, de Graaf G, Leroy R, Cleemput I. Horizon scanning for pharmaceuticals: proposal for the BeNeLuxA collaboration. Brussel: Belgian Health Care Knowledge Centre (KCE), 2017. Report No.: D/2017/10.273/15
- [35] ZINL. Horizonscan Geneesmiddelen: Over Horizonscan Geneesmiddelen. Den Haag: Zorginstituut Nederland, 2020. Available from: <https://www.horizonscangeneesmiddelen.nl/over-horizonscan-geneesmiddelen/over-horizonscan-geneesmiddelen> (accessed 7 June 2020).
- [36] ZINL. Horizonscan Geneesmiddelen. Den Haag: Zorginstituut Nederland, 2019. Available from: <https://www.horizonscangeneesmiddelen.nl/geneesmiddelen> (accessed 7 June 2020).
- [37] Sekretariatet for nye metoder. Nye metoder. 2020. Available from: <https://nyemetoder.no/english> (accessed 30 May 2020).
- [38] NOMA. Horizon scanning. Oslo, 2020. Available from: <https://legemiddelverket.no/english/public-funding-and-pricing/horizon-scanning> (accessed 30 May 2020).

- [39] Sekretariatet for nye metoder. Guidance criteria for management of medical devices in the National System for Managed Introduction of New Health Technologies within the Specialist Health Service in Norway. 2020. Available from: <https://nyemetoder.no/Documents/Om%20systemet/Guidance%20criteria%20for%20handling%20medical%20devices%20in%20Nye%20metoder.pdf> (accessed 30 May 2020).
- [40] Sekretariatet for nye metoder. Metodevarslene (Horizon scanning). 2020. Available from: <https://nyemetoder.no/om-systemet/metodevarsling> (accessed 30 May 2020).
- [41] Norwegian Institute of Public Health. MedNytt. 2020. Available from: <https://www.helsebiblioteket.no/mednytt> (accessed 30 May 2020).
- [42] Region Stockholms. Horizon scanning. Stockholm, 2020. Available from: <https://www.janusinfo.se/nationelltinforandeavlakemedel/managedintroductionthisishowitworks/inenglish/horizonscanning.5.4771ab7716298ed82ba97406.html> (accessed 30 May 2020).
- [43] Wettermark B. Horizon scanning & forecasting drug utilization in Sweden. Managed introduction of new medicines. III° PIPERSKA Workshop, 11–13 May 2015 - Warsaw, Poland. 2015. Available from: [http://www.piperska.org/sites/default/files/Wettermark\\_Horizon\\_scanning\\_and\\_forecasting\\_in\\_Sweden.pdf](http://www.piperska.org/sites/default/files/Wettermark_Horizon_scanning_and_forecasting_in_Sweden.pdf) (accessed 31 May 2020).
- [44] Björn W, Brian G, Cecilia E, van Ganse Eric, Silvio G, Roberta J, et al. Einführung neuer Arzneimittel in europäische Gesundheitssysteme (Introduction of New Medicines into European Healthcare Systems). *Gesundheit Gesellschaft Wissenschaft (GGW)*. 2010;10(3): 24-34.
- [45] Eriksson I, von Euler M, Malmström RE, Godman B, Wettermark B. Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System. *Applied Health Economics and Health Policy*. 2019;17(1): 93-101.
- [46] Region Stockholms. Horizon scanning. Tidiga bedömningsrapporter. Stockholm, 2020. Available from: <https://www.janusinfo.se/nationelltinforandeavlakemedel/horizonscanning.4.728c0e316219da813569ab4.html> (accessed 31 May 2020).
- [47] Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United kingdom. *International Journal of Technology Assessment in Health Care*. 2012;28(3): 308-14.
- [48] Department of Health and the Association of the British Pharmaceutical Industry. The Pharmaceutical Price Regulation Scheme 2009. London, 2008. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/207462/dh\\_098498.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/207462/dh_098498.pdf) (accessed 7 June 2020).
- [49] UK PharmaScan. An Essential Step to Improve NHS Market Access for Medicines. London, Available from: [https://www.ukpharmascan.org.uk/Content/UK\\_PharmaScan\\_Flyer.pdf](https://www.ukpharmascan.org.uk/Content/UK_PharmaScan_Flyer.pdf) (accessed 31 May 2020).
- [50] Association of the British Pharmaceutical Industry (ABPI). UK PharmaScan. An Essential Step to Improve NHS Market Access for Medicines. London, Available from: <https://www.abpi.org.uk/media/7635/uk-pharmascan-information-leaflet.pdf> (accessed 31 May 2020).
- [51] Department of Health. Horizon Scanning: UK PharmaScan (unpublished presentation). Prague: PPRI Network Meeting, 19 March 2015, 2015.
- [52] Scottish Medicines Consortium (SMC). Horizon scanning. Glasgow, Available from: <https://www.scottishmedicines.org.uk/about-us/horizon-scanning/> (accessed 31 May 2020).
- [53] Varnava A, Bracchi R, Samuels K, Hughes DA, Routledge PA. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. *Pharmacoconomics*. 2018;36(5): 613-24.
- [54] Beneluxa Initiative. Horizon scanning. Available from: <https://beneluxa.org/horizonscanning> (accessed 7 June 2020).
- [55] de Block M. België slaat handen in elkaar met 8 andere landen om geneesmiddelen betaalbaar te houden (Belgium joins forces with 8 other countries to keep medicines affordable). 29 October 2019. Available from: <https://www.maggiedeblock.be/belgie-slaat-handen-in-elkaar-met-8-andere-landen-om-geneesmiddelen-betaalbaar-te-houden/> (accessed 7 June 2020).
- [56] Beneluxa Initiative. Archive. Available from: <https://beneluxa.org/archive> (accessed 7 June 2020).

- [57] IHSI. IHSI Joint Horizon Scanning Database - Tender. International Horizon Scanning Initiative, Available from: <https://ihsi-health.org/tender/> (accessed 7 June 2020).
- [58] Douw K, Vondeling H. Selection of new health technologies for assessment aimed at informing decision making: A survey among horizon scanning systems. *International journal of technology assessment in health care*. 2006;22(2): 177-83.
- [59] Douw K, Vondeling H, Eskildsen D, Simpson S. Use of the Internet in scanning the horizon for new and emerging health technologies: a survey of agencies involved in horizon scanning. *Journal of Medical Internet Research*. 2003;5(1): e6.
- [60] Grössmann N, Wolf S, Rosian K, Wild C. Pre-reimbursement: early assessment for coverage decisions. *Wiener Medizinische Wochenschrift*. 2019;169(11): 254-62.
- [61] Nachtnebel A, Breuer J, Willenbacher W, Bucsecs A, Krippel P, Wild C. Looking back on 5 years of horizon scanning in oncology. *International Journal of Technology Assessment in Health Care*. 2016;32(1-2): 54-60.
- [62] Nachtnebel A, Geiger-Gritsch S, Hintringer K, Wild C. Scanning the horizon: development and implementation of an early awareness system for anticancer drugs in Austria. *Health Policy*. 2012;104(1): 1 - 11.
- [63] Oortwijn W, Sampietro-Colom L, Habens F, Trowman R. How can health systems prepare for new and emerging health technologies? The role of horizon scanning revisited. *International Journal of Technology Assessment in Health Care*. 2018;34(3): 254-9.
- [64] Aanes T. Budgeting for new medicines and procurement strategy development. Managed introduction of new medicines. III° PIPERSKA Workshop, 11–13 May 2015 - Warsaw, Poland. 2015. Available from: [http://www.piperska.org/sites/default/files/Aanes\\_Drug\\_procurement\\_cooperation.pdf](http://www.piperska.org/sites/default/files/Aanes_Drug_procurement_cooperation.pdf) (accessed 31 May 2020).
- [65] Vogler S, Haasis MA, van den Ham R, Suleman F, Humbert T, Garner S. Cross-country collaborations to improve access to medicines and vaccines in the WHO European Region. Copenhagen: WHO Regional Office for Europe, 2020.
- [66] Douw K, Vondeling H, Oortwijn W. Priority setting for horizon scanning of new health technologies in Denmark: Views of health care stakeholders and health economists. *Health Policy*. 2006;76(3): 334-45.

## **Acknowledgements**

Sincere thanks go to the members of the Pharmaceutical Pricing and Reimbursement Information (PPRI) network: experts working in public authorities in several countries who are not mentioned by name in compliance with the PPRI policy.

Furthermore, I thank my colleague Nina Zimmermann for her involvement in the 2014 and 2019 surveys with the PPRI network and for reviewing an earlier draft of this article.

## **Funding**

The Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection has been funding the work of the PPRI Secretariat to manage and maintain the PPRI network.

Die systematische Bewertung medizinischer Prozesse und Verfahren, *Health Technology Assessment* (HTA), ist mittlerweile integrierter Bestandteil der Gesundheitspolitik. HTA hat sich als wirksames Mittel zur Sicherung der Qualität und Wirtschaftlichkeit im deutschen Gesundheitswesen etabliert.

Seit Einrichtung der Deutschen Agentur für HTA des DIMDI (DAHTA@DIMDI) im Jahr 2000 gehören die Entwicklung und Bereitstellung von Informationssystemen, speziellen Datenbanken und HTA-Berichten zu den Aufgaben des DIMDI.

Das DIMDI wurde gemäß Artikel 16a des Medizinprodukte-EU-Anpassungsgesetzes am 26. Mai 2020 in das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) eingegliedert.

Im Rahmen der Forschungsförderung beauftragte das DIMDI qualifizierte Wissenschaftlerinnen und Wissenschaftler mit der Erstellung von HTA-Berichten, die Aussagen machen zu Nutzen, Risiko, Kosten und Auswirkungen medizinischer Verfahren und Technologien mit Bezug zur gesundheitlichen Versorgung der Bevölkerung. Dabei fallen unter den Begriff Technologie sowohl Medikamente als auch Instrumente, Geräte, Prozeduren, Verfahren sowie Organisationsstrukturen. Vorrang haben dabei Themen, für die gesundheitspolitischer Entscheidungsbedarf besteht.